Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer

被引：0

作者：

Motta, R. ^{[1
]}

Cardona, A. ^{[2
]}

Cruz, G. ^{[3
]}

Aliaga, C. ^{[1
]}

Carracedo, C. ^{[1
]}

Raez, L. ^{[4
]}

Arrieta, O. ^{[3
]}

Mezquita, L. ^{[5
]}

Albarran, V. ^{[5
]}

Corrales, L. ^{[6
]}

Bacon, L. ^{[7
]}

Rojas, L.

Zuluaga, J.

Martin, C. ^{[8
]}

Dabalsa, A. ^{[4
]}

Ruiz-Patino, A. ^{[9
]}

Freitas, H. ^{[10
]}

Cordeiro, V. ^{[10
]}

Failoc-Rojas, V. ^{[1
]}

机构：

[1] ALIADA Canc Ctr, Lima, Peru

[2] Luis Carlos Sarmiento Angulo Canc Treatment & Res, Bogota, Colombia

[3] Inst Nacl Cancerol, Mexico City, DF, Mexico

[4] Mem Canc Inst, Hollywood, FL USA

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] CIMCA, San Jose, Costa Rica

[7] Hosp Vivian Pellas, Managua, Nicaragua

[8] Alexander Fleming Inst, Buenos Aires, DF, Argentina

[9] Fdn FICMAC, Bogota, Colombia

[10] AC Camargo Canc Ctr, Sao Paulo, Brazil

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

NSCLC; EGFR; Exon20; insertion;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP12.01-61

引用

页码：S666 / S666

页数：1

共 50 条

[21] The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
Zhao, Chao
Jiang, Tao
Li, Jiayu
Wang, Yan
Su, Chunxia
Chen, Xiaoxia
Ren, Shengxiang
Li, Xuefei
Zhou, Caicun
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1149 - +
[22] Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
Yang Li
Yunfeng Ni
Feng Lv
Yan Shi
Yedan Chen
Xiaoying Wu
Jiaohui Pang
Long Huang
Yang Shao
Tao Wang
Jie Min
Yang Song
BMC Medicine, 23 (1)
[23] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse
Paul H. Huang
Signal Transduction and Targeted Therapy, 4
[24] Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
van Veggel, B.
van der Wekken, A.
Hashemi, S.
Cornelissen, R.
Monkhorst, K.
Heideman, D.
Radonic, T.
Smit, E. F.
Schuuring, E.
De Langen, J.
ANNALS OF ONCOLOGY, 2018, 29
[25] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, Simon
Huang, Paul H.
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
[26] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
van Veggel, B.
Santos, J. F. Vilacha Madeira R.
Hashemi, S. M. S.
Paats, M. S.
Monkhorst, K.
Heideman, D. A. M.
Groves, M.
Radonic, T.
Smit, E. F.
Schuuring, E.
van der Wekken, A. J.
de Langen, A. J.
LUNG CANCER, 2020, 141 : 9 - 13
[27] Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan
Udagawa, H.
Matsumoto, S.
Ohe, Y.
Satouchi, M.
Furuya, N.
Kim, Y. H.
Seto, T.
Soejima, K.
Hayakawa, D.
Kato, T.
Miyamoto, S.
Ohashi, K.
Saeki, S.
Ohta, H.
Fujimoto, D.
Sekine, A.
Yoh, K.
Goto, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S224 - S224
[28] Efficacy of various types of chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 in-frame insertions.
Tang, Haibo
Li, Xiaoning
Cai, Jianhong
Wu, Xiaomin
Zheng, Yating
Huang, Mengli
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Mechanisms of resistance to CLN-081 (TAS6417) in non-small cell lung cancer with EGFR exon 20 insertions
Hayashida, Takuma
Kagawa, Yosuke
Mori, Shunta
Jie, Liu
Kashima, Yukie
Tanaka, Kosuke
Udagawa, Hibiki
Izumi, Hiroki
Kobayashi, Susumu
CANCER RESEARCH, 2022, 82 (12)
[30] Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions
Christopoulos, P.
Ou, S-H. I.
Lin, J.
Berg, D.
Hong, J-L.
Yin, Y.
Lin, J.
Bunn, V.
Lin, H. M.
Mehta, M.
Thomas, M.
ANNALS OF ONCOLOGY, 2021, 32 : S972 - S972

← 1 2 3 4 5 →